laboratori corpor america hold
diagnost tool
beat commentari mix lower
estim share loss pt
lh deliv beat narrow guid typic good enough
keep stock flat least street need lower outlook lh expect
share loss contract think today pullback attribut
realiti estim high given situat slight miss
covanc concern lh achiev slightli rais covanc guid
brief secur breach occur earli juli expect volum
lh affirm revenue impact higher denial test vitamin
reduct hcvg test said big pictur intact reiter
buy trim pt ep lh trade ntm ep
unh/aet surprisingli lh acknowledg expect see neg impact
revenu profit result lose exclus
partial off-set volum gain aet said lh acknowledg
pleas in-network price contract aet next year
us suggest lh lose volum make revenue loss
higher price expect share shift gradual recal lh today
deriv lab rev
result adj ep beat street line
rev y/i beat driven
beat dx busi partial off-set miss vs estim
lh dx rev beat /street volum
rose strong beat organ volum help
beat ad point growth rev/req
level miss pama cut strong volum
lower price test lh lh acknowledg revenu
volum headwind relat limit coverag polici vitamin
covanc rev miss street
fx ad growth lh indic organ growth covanc
hover mid-to-high singl digit quantifi specif organ growth
growth came chiltern acquisit lh indic
earli develop segment strong clinic central lab work shift
covanc backlog lh expect
convert revenue net order came
net book-to-bil
guid lh tighten revenue guid y/i
reflect divestitur food solut busi off-set
increas covanc guid lh tighten adj ep guid
lh expect rev diagnost
reflect divestitur food solut
due chiltern higher investig fee pass-through revenu
covanc note chiltern anniversari
model chang model comment next page
price close busi juli
labcorp lead refer laboratori test
compani also oper covanc drug
canaccord genuiti global capit market group canaccord genuiti group inc cf tsx
recommend opinion express research report accur reflect research analyst person independ object view
compani secur subject report discuss herein
import inform pleas see import disclosur begin page document
laboratori corpor america hold
beat commentari mix
lower estim share loss pt
lt thesi intact reiter buy
lh deliv beat narrow guid typic good
enough keep stock flat least street need lower
outlook lh expect share loss contract think today
pullback attribut realiti estim high given
situat slight miss covanc concern lh achiev
slightli rais covanc guid brief secur breach
occur earli juli expect volum lh affirm
revenue impact higher denial test vitamin
reduct hcvg test said big pictur intact reiter
buy rate reiter lh top pick howev trim pt
lower adj ep estim
share lh trade ntm ep well peak
multipl prior great recess believ lh deliv
multipl expans execut strateg initi
unh/aet surprisingli lh acknowledg expect see
neg impact revenu profit result lose
exclus partial off-set volum gain aet
said lh acknowledg pleas in-network price
contract aet next year us suggest
lh lose volum make revenue loss higher
price expect share shift gradual recal lh today
deriv lab rev
result adj ep beat street line
rev y/i beat
driven beat dx busi partial off-set
miss vs estim
lh dx rev beat /street
volum rose strong beat organ
volum help beat ad
point growth rev/req level
miss pama cut strong volum
lower price test lh lh acknowledg revenu volum
headwind relat limit coverag polici vitamin
covanc rev miss street
fx ad growth lh indic organ growth
covanc hover mid-to-high singl digit quantifi
specif organ growth growth came chiltern
acquisit lh indic earli develop segment strong
clinic central lab work shift covanc
backlog lh expect convert
buy unchang target price juli
diagnost tool
laboratori corpor america hold
revenue net order came net book-
to-bil
guid lh tighten revenue guid
y/i reflect divestitur food solut busi
off-set increas covanc guid lh tighten adj ep guid
lh expect rev
diagnost reflect divestitur food
solut due chiltern higher
investig fee pass-through revenu covanc note
chiltern anniversari
model chang trim volum outlook total volum grew
robust driven healthi organ volum
acquisit note lh acquisit mount sinai outreach busi
paml exclud certain relat jv annual may thu
growth rate deceler model dx rev
volum rev/req
model dx rev near high end guid
lower rev/req year
lower estim mainli expect share loss net
win aet contract lower revenu volum
rev/req estim reflect share loss unit contract coupl
headwind relat pama well text mix lower rev
also lower adj
ep lower dx rev driven
growth volum headwind rev/req lh
pleas commerci rate negoti aet
compani comment mix shift headwind relat
req/req instanc lh strong volum growth come
lower rev/req compani also assum continu headwind relat
pama look total covanc growth y/i
remind compani acquisit chiltern drug develop
busi anniversari lh believ drug develop
busi track mid-to-upp singl digit organ growth
today ink big deal gsk gsk today
announc exclus four-year agreement aim toward
identifi novel drug target collabor focu research
develop innov new medicin potenti cure use human
genet basi discoveri bring tabl genet data
custom gsk offer scientif medic knowledg
regard drug develop commerci recal
custom consent particip research
specif goal collabor includ
improv target select allow safer effect precis
medicin discov
buy unchang target price juli
diagnost tool
laboratori corpor america hold
support identif patient subgroup like
respond target treatment
allow effect identif recruit patient
term deal gsk enter four-year
collabor option extend fifth year gsk
becom exclus collabor drug target discoveri
program time compani use rich databas
proprietari statist analyt fuel drug target discoveri goal
jointli discov novel target progress develop joint
drug discoveri team use combin resourc
identifi new target prioritis base strength biolog
hypothesi possibl find medicin clinic opportun
allow work commenc immedi deal enabl compani
bring exist earli stage programm within collabor
current portfolio earli stage therapeut research programm
across wide rang diseas indic assess
inclus gsk contribut inhibitor current
preclin develop potenti treatment parkinson diseas
programm expect significantli progress leverag
larg base consent custom awar variant
statu result fda-authoris genet health report
togeth gsk expect effect target
rapidli recruit patient defin mutat order reach
clinic proof concept
activ within collabor initi co-fund
either compani certain right reduc fund share
collabor programm expect collabor jointli
progress number target per year either compani abl
independ progress addit target identifi within collabor
gsk also right work analys
databas valid gsk exist therapeut portfolio well
leverag capabl clinic trial recruit gsk
share proce new treatment medicin
aris collabor
addit gsk made equiti invest
call lh character nice compon
growth though didnt break exact contribut lh consid
key strateg collabor thought partner data manag
buy unchang target price juli
diagnost tool
laboratori corpor america hold
secur breach last monday lh announc detect suspici
activ inform technolog network weekend issu
temporarili affect lh test process custom access test result
prior weekend lh call indic ransomwar
event caus take certain system offlin protect patient inform
accord lh independ forens expert found evid theft
misus data though disrupt requir recov lh
assess financi volum impact event incur
cost relat remedi effort lh believ earli determin
volum impact time expect impact
consid signific enough chang full year guid
walgreen partnership expand locat lh intend expand
footprint walgreen partnership stand store
store late februari analyst day februari lh indic
patient come lh/ walgreen clinic new custom lh
earli read lh reach peopl retail lh survey data
indic consum vs doc indic
involv decis get test
hcv prescript drug monitor vitamin saw volum growth
limit coverag polici serv off-set revenu growth lh
indic hcv busi overal vitamin prescript drug
monitor test categori deliv posit volum growth y/i
deliv substanti growth quarter lh conced
revenu constrain limit coverag polici restrict
payment polici preauthor polici implement payer
effort control lab spend curb bill fraud primarili gear toward
similar lh see declin hcv genotyp volum
view neg headwind buy-rat genmark howev lh
indic hcv genotyp small overal hcv test volum
thu impact lh small
covanc backlog covanc backlog lh
expect convert revenue net order came
net book-to-bil lh covanc
revenu miss estim lh note
book shift expect see slight variat book-
to-bil ratio depend strength award fall back end
ttm rang strength book quarter
expect outweigh buyback lh repurchas
stock remain
author lh invest acquisit lh
end billion debt hover gross leverag ratio
ebitda end recal compani leverag
target lh guidanc contempl free cash flow
billion unchang expect see acquisit not-too-
distant futur certainli lh invest deal
expect lh priorit
buy unchang target price juli
diagnost tool
laboratori corpor america hold
pama chanc tweak patient await updat acla vs
hh lawsuit labcorp ceo consid compel power
case acla acla ask go back congress said
would provid market-bas price inclus larger
pool lab lh ceo dave king hold optim rate could
adjust year believ stock
price outcom like believ may see relief
form less draconian rate-set year think may
visibl within next month
cover compani mention report
buy unchang target price juli
diagnost tool
laboratori corpor america hold
compani report canaccord genuiti estim detail financi model includ balanc sheet incom statement cash flow project avail may obtain contact canaccord genuiti sale person author analyst whose contact
inform appear front page report
buy unchang target price juli
diagnost tool
laboratori corpor america hold
buy unchang target price juli
diagnost tool
canaccord genuiti estim compani report
laboratori corpor america hold
buy unchang target price juli
diagnost tool
laboratori corpor america hold
canaccord genuiti estim compani report
buy unchang target price juli
diagnost tool
laboratori corpor america hold
